Get Involved
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
Study Purpose
This phase II trial studies the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with melanoma that can be treated by surgery (operable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with CMP-001 may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. The addition of CMP-001 to pembrolizumab could improve the ability of the immune system to shrink tumors and to prevent them from returning.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 18 Years and Over |
| Gender | All |
Inclusion Criteria:
- - Patient must be >= 18 years of age.
- - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- - Patient must have a histologic diagnosis of melanoma belonging to the following American Joint Committee on Cancer (AJCC) 8th edition TNM stages: - T0, Tx or T1-4; and.
- - N1b, N2b, N2c, N3b or N3c.
- - Patients may have a presentation with primary melanoma with concurrent regional nodal and/or in-transit metastasis; or patients may have a history of primary melanoma or unknown primary melanoma presenting with clinically detected regional nodal and/or in-transit recurrence; and may belong to any of the following groups: - Primary cutaneous melanoma with clinically apparent regional lymph node metastases and/or in-transit metastases.
- - Clinically detected recurrent melanoma at the proximal regional lymph node(s) basin.
- - Primary cutaneous melanoma with concurrent nodal disease involving a single (or multiple) regional nodal group(s) if considered potentially surgically resectable at baseline.
- - Clinically detected nodal melanoma (if single site) arising from an unknown primary.
- - In-transit cutaneous metastases with or without regional lymph node involvement permitted if considered potentially surgically resectable at baseline.
- - NOTE: Patients with mucosal and/or uveal melanoma are not eligible for the study.
- - Patient must be a candidate for definitive surgery and have met with the treating surgical oncologist prior to randomization.
- - Patient must not have received any live vaccine within 30 days prior to randomization and while participating in the study.
- - Patient must have the presence of injectable and measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, documented by scans obtained within 4 weeks prior to randomization.
- - NOTE: Injectable disease is defined as an accessible lesion in the skin, subcutaneous tissue or lymph nodes (LN) close to the skin and palpable by physical examination or approachable with ultrasound guidance.
- - Absolute neutrophil count (ANC) >= 1,500 /mcL (obtained within 4 weeks prior to randomization) - Hemoglobin (Hgb) >= 9 g/dL or >= 5.6 mmol/L (obtained within 4 weeks prior to randomization) - Platelets >= 100,000 / mcL (obtained within 4 weeks prior to randomization) - Serum creatinine =< 1.5 x institutional upper limit of normal (ULN) or measured or calculated creatinine clearance > 60 mL/min (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl] for patients with creatinine levels > 1.5 x institutional ULN) (obtained within 4 weeks prior to randomization) - Serum total bilirubin =< 1.5 x institutional ULN; for total bilirubin level > 1.5 x ULN but =< 3 x ULN, the direct bilirubin must be =< the institutional ULN (obtained within 4 weeks prior to randomization) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (obtained within 4 weeks prior to randomization) - International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x institutional ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (obtained within 4 weeks prior to randomization) - Activated partial thromboplastin time (aPTT) =< 1.5 x institutional ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (obtained within 4 weeks prior to randomization) - Patients must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
- - Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or abstaining from sexual intercourse from time of randomization, while on study treatment, and continue for 26 weeks after the last dose of protocol treatment.
- - Patient must have the ability to understand and the willingness to sign a written informed consent document.
- - Patient must not have received prior systemic therapy for melanoma including systemic therapy with an anti-PD-1, anti-PD-L1, anti-CTLA-4, BRAF/MEK inhibitor combination and/or TLR-9 agonist.
- - Patient must not have a diagnosis of immunodeficiency or be receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization, except as noted here.
- - Patients who are currently receiving steroids at a dose of prednisone =< 5 mg daily (or equivalent) are permitted to enroll.
- - Patients who require topical, ophthalmologic and inhalational steroids are permitted to enroll.
- - Patients with hypothyroidism who are stable on hormone replacement are permitted to enroll.
- - Patients who require active immunosuppression with corticosteroids at a dose of prednisone > 5 mg daily (or equivalent) for any reason are ineligible.
- - Patients with adrenal insufficiency are ineligible.
- - Patients who have developed autoimmune disorders of grade 4 while on prior immunotherapy are not permitted to enroll on this study.
- - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to randomization are eligible for this trial.
- - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
- - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured.
- - Patients with a history of brain metastases are not eligible for this study as they do not meet the eligibility staging criteria.
- - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.
- - Patient must not have had an allogeneic tissue/solid organ transplant.
- - Patient must not have a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- - Patient must not have severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients.
- - Patient must not have an active infection requiring systemic therapy.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT04708418 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 2 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
National Cancer Institute (NCI) |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Ahmad Tarhini |
| Principal Investigator Affiliation | ECOG-ACRIN Cancer Research Group |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
NIH |
| Overall Status | Active, not recruiting |
| Countries | United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma |
PRIMARY OBJECTIVE:
- I. To evaluate the rate of pathologic complete response (pCR) rate in patients in each arm.
- I. To evaluate the rate of pathologic near-complete/major response (pMR) of the neoadjuvant therapy in each arm.
- II. To evaluate the pathologic response rate of un-injected lesions on the combination arm (Arm B).
- III. To evaluate relapse-free survival (RFS) in each arm.
- IV. To evaluate overall survival (OS) in each arm.
- V. To evaluate the preoperative radiographic response rate in each arm.
- VI. To evaluate safety and toxicity of neoadjuvant therapy in each arm.
Arms
Experimental: Arm A (pembrolizumab)
NEOADJUVANT PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase. ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial.
Experimental: Arm B (CMP-001, pembrolizumab)
NEOADJUVANT PHASE: Patients receive CMP-001 SC on day 1 of cycle 1 and then intratumorally on days 8 and 15 of cycle 1, days 1, 8, and 15 of cycle 2, and day 1 of cycle 3. Patients also receive pembrolizumab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase. ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial.
Interventions
Procedure: - Biopsy Procedure
Undergo biopsy
Procedure: - Biospecimen Collection
Undergo collection of blood samples
Procedure: - Computed Tomography
Undergo CT or PET/CT
Biological: - Pembrolizumab
Given IV
Procedure: - Positron Emission Tomography
Undergo PET/CT
Procedure: - Surgical Procedure
Undergo surgery
Drug: - VLP-encapsulated TLR9 Agonist CMP-001
Given SC or intratumorally
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, 98508
Status
Address
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, 99508
Status
Address
Alaska Oncology and Hematology LLC
Anchorage, Alaska, 99508
Status
Address
Alaska Women's Cancer Care
Anchorage, Alaska, 99508
Status
Address
Anchorage Oncology Centre
Anchorage, Alaska, 99508
Status
Address
Katmai Oncology Group
Anchorage, Alaska, 99508
Status
Address
Providence Alaska Medical Center
Anchorage, Alaska, 99508
Status
Address
Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
Status
Address
Banner University Medical Center - Tucson
Tucson, Arizona, 85719
Status
Address
University of Arizona Cancer Center-North Campus
Tucson, Arizona, 85719
Status
Address
Mercy Hospital Fort Smith
Fort Smith, Arkansas, 72903
Status
Address
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, 91505
Status
Address
Epic Care-Dublin
Dublin, California, 94568
Status
Address
Bay Area Breast Surgeons Inc
Emeryville, California, 94608
Status
Address
Epic Care Partners in Cancer Care
Emeryville, California, 94608
Status
Address
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Status
Address
Alta Bates Summit Medical Center - Summit Campus
Oakland, California, 94609
Status
Address
Bay Area Tumor Institute
Oakland, California, 94609
Status
Address
Saint Joseph Hospital - Orange
Orange, California, 92868
Status
Address
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868
Status
Address
Epic Care Cyberknife Center
Walnut Creek, California, 94597
Status
Address
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, 80012
Status
Address
The Medical Center of Aurora
Aurora, Colorado, 80012
Status
Address
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Status
Address
Rocky Mountain Cancer Centers - Centennial
Centennial, Colorado, 80112
Status
Address
Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado, 80218
Status
Address
Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, 80218
Status
Address
Rocky Mountain Cancer Centers-Rose
Denver, Colorado, 80220
Status
Address
Mountain Blue Cancer Care Center - Swedish
Englewood, Colorado, 80113
Status
Address
Rocky Mountain Cancer Centers - Swedish
Englewood, Colorado, 80113
Status
Address
Swedish Medical Center
Englewood, Colorado, 80113
Status
Address
The Melanoma and Skin Cancer Institute
Englewood, Colorado, 80113
Status
Address
Banner North Colorado Medical Center
Greeley, Colorado, 80631
Status
Address
Rocky Mountain Cancer Centers-Littleton
Littleton, Colorado, 80120
Status
Address
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, Colorado, 80124
Status
Address
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Status
Address
Banner McKee Medical Center
Loveland, Colorado, 80539
Status
Address
Rocky Mountain Cancer Centers-Thornton
Thornton, Colorado, 80260
Status
Address
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida, 33180
Status
Address
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, 33146
Status
Address
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442
Status
Address
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
Status
Address
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, 33324
Status
Address
Saint Luke's Cancer Institute - Boise
Boise, Idaho, 83712
Status
Address
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho, 83619
Status
Address
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho, 83642
Status
Address
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho, 83687
Status
Address
Saint Luke's Cancer Institute - Twin Falls
Twin Falls, Idaho, 83301
Status
Address
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Status
Address
Illinois CancerCare-Canton
Canton, Illinois, 61520
Status
Address
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Status
Address
SIH Cancer Institute
Carterville, Illinois, 62918
Status
Address
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Status
Address
Centralia Oncology Clinic
Centralia, Illinois, 62801
Status
Address
University of Illinois
Chicago, Illinois, 60612
Status
Address
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Status
Address
Decatur Memorial Hospital
Decatur, Illinois, 62526
Status
Address
Illinois CancerCare-Dixon
Dixon, Illinois, 61021
Status
Address
Crossroads Cancer Center
Effingham, Illinois, 62401
Status
Address
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Status
Address
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Status
Address
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
Status
Address
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Status
Address
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Status
Address
SSM Health Good Samaritan
Mount Vernon, Illinois, 62864
Status
Address
Cancer Care Center of O'Fallon
O'Fallon, Illinois, 62269
Status
Address
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Status
Address
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
Status
Address
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
Status
Address
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
Status
Address
Illinois CancerCare-Peru
Peru, Illinois, 61354
Status
Address
Valley Radiation Oncology
Peru, Illinois, 61354
Status
Address
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Status
Address
Southern Illinois University School of Medicine
Springfield, Illinois, 62702
Status
Address
Springfield Clinic
Springfield, Illinois, 62702
Status
Address
Springfield Memorial Hospital
Springfield, Illinois, 62781
Status
Address
Illinois CancerCare - Washington
Washington, Illinois, 61571
Status
Address
Reid Health
Richmond, Indiana, 47374
Status
Address
Mary Greeley Medical Center
Ames, Iowa, 50010
Status
Address
McFarland Clinic - Ames
Ames, Iowa, 50010
Status
Address
McFarland Clinic - Boone
Boone, Iowa, 50036
Status
Address
McFarland Clinic - Trinity Cancer Center
Fort Dodge, Iowa, 50501
Status
Address
McFarland Clinic - Jefferson
Jefferson, Iowa, 50129
Status
Address
McFarland Clinic - Marshalltown
Marshalltown, Iowa, 50158
Status
Address
Central Care Cancer Center - Garden City
Garden City, Kansas, 67846
Status
Address
Central Care Cancer Center - Great Bend
Great Bend, Kansas, 67530
Status
Address
Louisiana Hematology Oncology Associates LLC
Baton Rouge, Louisiana, 70809
Status
Address
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Status
Address
Terrebonne General Medical Center
Houma, Louisiana, 70360
Status
Address
Bronson Battle Creek
Battle Creek, Michigan, 49017
Status
Address
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan, 49503
Status
Address
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
Grand Rapids, Michigan, 49503
Status
Address
Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan, 49503
Status
Address
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Status
Address
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Status
Address
Beacon Kalamazoo Cancer Center
Kalamazoo, Michigan, 49009
Status
Address
Beacon Kalamazoo
Kalamazoo, Michigan, 49048
Status
Address
Trinity Health Muskegon Hospital
Muskegon, Michigan, 49444
Status
Address
Corewell Health Lakeland Hospitals - Niles Hospital
Niles, Michigan, 49120
Status
Address
Cancer and Hematology Centers of Western Michigan - Norton Shores
Norton Shores, Michigan, 49444
Status
Address
Corewell Health Reed City Hospital
Reed City, Michigan, 49677
Status
Address
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
Saint Joseph, Michigan, 49085
Status
Address
Corewell Health Lakeland Hospitals - Saint Joseph Hospital
Saint Joseph, Michigan, 49085
Status
Address
Munson Medical Center
Traverse City, Michigan, 49684
Status
Address
University of Michigan Health - West
Wyoming, Michigan, 49519
Status
Address
Mercy Oncology and Hematology - Clayton-Clarkson
Ballwin, Missouri, 63011
Status
Address
Central Care Cancer Center - Bolivar
Bolivar, Missouri, 65613
Status
Address
Mercy Cancer Center - Cape Girardeau
Cape Girardeau, Missouri, 63703
Status
Address
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Status
Address
Parkland Health Center - Farmington
Farmington, Missouri, 63640
Status
Address
MU Health Care Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
Status
Address
Freeman Health System
Joplin, Missouri, 64804
Status
Address
Mercy Hospital Joplin
Joplin, Missouri, 64804
Status
Address
Mercy Clinic-Rolla-Cancer and Hematology
Rolla, Missouri, 65401
Status
Address
Phelps Health Delbert Day Cancer Institute
Rolla, Missouri, 65401
Status
Address
Heartland Regional Medical Center
Saint Joseph, Missouri, 64506
Status
Address
Mercy Hospital South
Saint Louis, Missouri, 63128
Status
Address
Missouri Baptist Medical Center
Saint Louis, Missouri, 63131
Status
Address
Mercy Hospital Saint Louis
Saint Louis, Missouri, 63141
Status
Address
Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri, 63670
Status
Address
Mercy Hospital Springfield
Springfield, Missouri, 65804
Status
Address
CoxHealth South Hospital
Springfield, Missouri, 65807
Status
Address
Missouri Baptist Sullivan Hospital
Sullivan, Missouri, 63080
Status
Address
BJC Outpatient Center at Sunset Hills
Sunset Hills, Missouri, 63127
Status
Address
Saint Patrick Hospital - Community Hospital
Missoula, Montana, 59802
Status
Address
Indu and Raj Soin Medical Center
Beavercreek, Ohio, 45431
Status
Address
Dayton Physicians LLC-Miami Valley South
Centerville, Ohio, 45459
Status
Address
Miami Valley Hospital South
Centerville, Ohio, 45459
Status
Address
Oncology Hematology Care Inc-Kenwood
Cincinnati, Ohio, 45236
Status
Address
Miami Valley Hospital
Dayton, Ohio, 45409
Status
Address
Dayton Physician LLC - Englewood
Dayton, Ohio, 45415
Status
Address
Miami Valley Hospital North
Dayton, Ohio, 45415
Status
Address
Armes Family Cancer Center
Findlay, Ohio, 45840
Status
Address
Blanchard Valley Hospital
Findlay, Ohio, 45840
Status
Address
Orion Cancer Care
Findlay, Ohio, 45840
Status
Address
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Status
Address
Dayton Physicians LLC-Atrium
Franklin, Ohio, 45005
Status
Address
Dayton Physicians LLC-Wayne
Greenville, Ohio, 45331
Status
Address
Wayne Hospital
Greenville, Ohio, 45331
Status
Address
Greater Dayton Cancer Center
Kettering, Ohio, 45409
Status
Address
Kettering Medical Center
Kettering, Ohio, 45429
Status
Address
Springfield Regional Cancer Center
Springfield, Ohio, 45504
Status
Address
Springfield Regional Medical Center
Springfield, Ohio, 45504
Status
Address
Dayton Physicians LLC - Troy
Troy, Ohio, 45373
Status
Address
Upper Valley Medical Center
Troy, Ohio, 45373
Status
Address
Mercy Hospital Oklahoma City
Oklahoma City, Oklahoma, 73120
Status
Address
Saint Charles Health System
Bend, Oregon, 97701
Status
Address
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Status
Address
Providence Cancer Institute Clackamas Clinic
Clackamas, Oregon, 97015
Status
Address
Bay Area Hospital
Coos Bay, Oregon, 97420
Status
Address
Providence Newberg Medical Center
Newberg, Oregon, 97132
Status
Address
Providence Portland Medical Center
Portland, Oregon, 97213
Status
Address
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Status
Address
Saint Luke's Cancer Center - Allentown
Allentown, Pennsylvania, 18104
Status
Address
Saint Luke's University Hospital-Bethlehem Campus
Bethlehem, Pennsylvania, 18015
Status
Address
Saint Luke's Hospital-Anderson Campus
Easton, Pennsylvania, 18045
Status
Address
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232
Status
Address
Saint Luke's Hospital-Quakertown Campus
Quakertown, Pennsylvania, 18951
Status
Address
Guthrie Medical Group PC-Robert Packer Hospital
Sayre, Pennsylvania, 18840
Status
Address
Avera Cancer Institute-Aberdeen
Aberdeen, South Dakota, 57401
Status
Address
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Status
Address
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
Status
Address
Central Vermont Medical Center/National Life Cancer Treatment
Berlin, Vermont, 05602
Status
Address
University of Vermont Medical Center
Burlington, Vermont, 05401
Status
Address
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Status
Address
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298
Status
Address
Providence Regional Cancer System-Aberdeen
Aberdeen, Washington, 98520
Status
Address
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Status
Address
Providence Regional Cancer System-Centralia
Centralia, Washington, 98531
Status
Address
Swedish Cancer Institute-Edmonds
Edmonds, Washington, 98026
Status
Address
Providence Regional Cancer Partnership
Everett, Washington, 98201
Status
Address
Swedish Cancer Institute-Issaquah
Issaquah, Washington, 98029
Status
Address
Kadlec Clinic Hematology and Oncology
Kennewick, Washington, 99336
Status
Address
Providence Regional Cancer System-Lacey
Lacey, Washington, 98503
Status
Address
PeaceHealth Saint John Medical Center
Longview, Washington, 98632
Status
Address
Jefferson Healthcare
Port Townsend, Washington, 98368
Status
Address
Swedish Medical Center-Ballard Campus
Seattle, Washington, 98107
Status
Address
Swedish Medical Center-First Hill
Seattle, Washington, 98122
Status
Address
PeaceHealth United General Medical Center
Sedro-Woolley, Washington, 98284
Status
Address
PeaceHealth Southwest Medical Center
Vancouver, Washington, 98664
Status
Address
Providence Saint Mary Regional Cancer Center
Walla Walla, Washington, 99362
Status
Address
Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin, 54701
Status
Address
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, 54449
Status
Address
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Status
Address
Marshfield Medical Center - Minocqua
Minocqua, Wisconsin, 54548
Status
Address
Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin, 54868
Status
Address
Marshfield Medical Center-River Region at Stevens Point
Stevens Point, Wisconsin, 54482
Status
Address
Marshfield Medical Center - Weston
Weston, Wisconsin, 54476
